Cooper Companies traded at $81.97 this Wednesday March 4th, decreasing $1.40 or 1.68 percent since the previous trading session. Looking back, over the last four weeks, Cooper Companies lost 2.33 percent. Over the last 12 months, its price fell by 10.25 percent. Looking ahead, we forecast Cooper Companies to be priced at 81.11 by the end of this quarter and at 73.89 in one year, according to Trading Economics global macro models projections and analysts expectations.
The Cooper Companies, Inc. is a global medical device company. The Company operates through two segments: CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing, and marketing a range of products for contact lens wearers, featuring advanced materials and optics. CooperVision designs its products to solve vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues, with a collection of spherical, toric and multifocal contact lenses. The CooperSurgical segment is focused on advancing the health of women, babies, and families through a diversified portfolio of products and services including medical devices, fertility, diagnostics and contraception. CooperSurgical's products are used in medical office and surgical procedures, primarily by obstetricians/gynecologists (OB/GYN); and fertility products/equipment and genetic testing services used primarily in fertility clinics and laboratories.